ViiV Healthcare announced new data from the Phase3b/4 STRIIVING study that evaluated the safety, efficacy, and tolerability of switching from an antiretroviral therapy (ART) to once-daily Triumeq (abacavir/dolutegravir/lamivudine) in virologically suppressed adults with HIV-1 infection (n=274).
STRIIVING was a randomized, open-label, multicenter study that enrolled patients switching from a range of ART that included protease inhibitor (n=234), integrase strand transfer inhibitor (n=146), and non-nucleoside reverse transcriptase inhibitor (n=171)-based regimens. The study met its primary endpoint in showing that viral suppression was non-inferior for patients switching to Triumeq (HIV RNA <50 copies/mL in intention to treat efficacy; n=551): 85% (Triumeq) vs. 88% (existing ART); and per protocol (n=435): 93% vs. 93%.
The study reported no patients with protocol defined virologic failure (HIV-1 RNA ≥400 copies/mL) and no patients were evaluated for treatment-emergent resistance in either study arm. Patients who switched to once-daily Triumeq also reported higher treatment satisfaction score improvements as measured by the HIV Treatment Satisfaction Questionnaire (adjusted difference 2.4; 95% CI: 1.3, 3.5; P<0.001).
Triumeq is a dolutegravir-based regimen that contains two nucleoside reverse transcriptase inhbiitors: abacavir and lamivudine. It is available as fixed-dose 600mg/50mg/300mg strength tablets in 30-count bottles.
For more information call (877) 356-8368 or visit Triumeq.com.